Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the ...

Pharmaceutical giant Novo Nordisk says an oral version of semaglutide — the active ingredient in blockbuster drugs Ozempic ...

Novo misses in Alzheimer's trial; Insurer shares rise on report Trump will unveil health policy proposal; Bayer’s stroke drug succeeds in late-stage trial.

A major new study has found that a drug called semaglutide can greatly improve heart health in people who are overweight or ...

A closely anticipated trial has concluded with disappointing results for Novo Nordisk's blockbuster drug semaglutide, the ...

Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...

Shares of Novo Nordisk (NYSE: NVO) fell on Monday, finishing down 5.6%. The drop comes as the S&P 500 and the Nasdaq ...

Tia here with news that a trial of the pill form of the GLP-1 drug semaglutide has failed to delay Alzheimer's progression in ...

Shares of Biogen rose 3% following news of Novo's Alzheimer's trial failure. Biogen and partner Eisai's Leqembi and rival Eli ...

Novo Nordisk A/S’ wild card bet that its GLP-1 receptor agonist semaglutide could be used to treat Alzheimer’s disease has ...

The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...

The biomarker improvements in the EVOKE studies are worth noting, observed Howard Fillit, MD, of the Alzheimer's Drug ...